Tsai YF et al. [34] reported that the anti-PF4/heparin antibody increases the risk of thromboembolic events, but they also determined that the anti-PF4/heparin antibody is not correlated with peripheral arterial disease (PAD) and coronary heart disease (CHD). Here, PF4 is linked to peripheral arterial disease.